Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Key2Compliance | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
A post-market-clinical follow-up investigation to confirm the clinical safety and performance profile of Decoria® Essence for the correction and improvement of lips profile.
A post-market, open-label, prospective, interventional, confirmatory, evaluator-blinded, multi - centre, clinical investigation to confirm the clinical safety and performance profile of Decoria® Essence for the correction and improvement of lips profile.
Subjects desiring correction and improvement of their lip profile at the participating sites will be asked to participate in the clinical investigation. According to national legislation, all subjects must have a consultation with the respective clinic and receive both oral and written information at least 48 hours prior to treatment with fillers, as to allow for sufficient reflection time.
If the subject decides to participate, the subject will receive treatment on Day 0 (Visit 1). At 1 month visit (Visit 2) an optional touch-up may be given as well as assessments performed. All subjects will be followed for 6 months with follow-up and assessments by visits in the clinic (Visit 2, Visit 3 and Visit 4).
Standardized facial photography will be taken prior to and after treatment during Visit 1 and 2 and during each follow-up visit at the clinic (Visit 3, Visit 4 and Visit 5). The photographs will be used for the evaluation of the primary efficacy endpoint of the blinded-evaluator using the Global Aesthetic Improvement Scale (GAIS) as well as the exploratory instrumental evaluation of the lip contour. GAIS will be used for blinded-evaluator assessment, treating Investigator assessment and patient satisfaction.
Numeric Pain Rating Scale (NRS) at each visit involving an injection (Visit 1 and Visit 2 - optional touch up) will be used to measure pain.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Investigational Medical Device | Other | All eligible subjects desiring improvement and correction of their lip profile will receive injection of Decoria Essence in either one or both lips (upper, lower) and/or vermillion lines and/or perioral wrinkles/rhytids. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Decoria Essence | Device | Decoria® Essence is a hyaluronic acid based, BDDE-crosslinked dermal filler. Decoria® Essence dermal fillers are injected into dermal tissue to improve the volume and the contouring of the lips to desired level of correction by supporting the overlying tissue. Injection volume will be determined by the treating investigator according to the instructions for Use (IFU). |
| Measure | Description | Time Frame |
|---|---|---|
| Primary efficacy endpoint to measure the change/improvement in score using the Global Aesthetic Improvement Scale (GAIS) | The primary efficacy endpoint is to measure the change/improvement in score from pre-treatment baseline to 3 months post treatment by an independent evaluator, using the Global Aesthetic Improvement Scale (GAIS). GAIS is a comparative scale, based on assessment of change since before pre-intervention, ranges from 1 (exceptional improvement) to 4 (unaltered) and 5 (worse). The blinded evaluator will compare the pre-intervention face to post-intervention face and assign the level of improvement in the lips according to the GAIS grading. Each lip (upper and lower) will be assessed independently. | From pre-intervention baseline (Visit 1, Day 0) to month 3 (Visit 3, Day 90). |
| Primary safety endpoint by evaluating Adverse Events | The primary safety endpoint is to assess the safety of Decoria® Essence, evaluated by the incidence, intensity, duration, and time of onset of related adverse events (AEs), including injection site reactions, collected during study duration. | From inclusion until the end of the study (6 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary endpoint evaluating pain by Numeric Pain Rating Scale (NRS) | Pain will be measured by numerical scale Numeric Pain Rating Scale (NRS) (11-point verbal score completed for each target region treated) for each visit involving an injection. 0 representing "no pain" and 10 indicating the "worst pain imaginable" | At baseline (Visit 1, Day 0) and optional touch-up (Visit 2, Day 30) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lucian Grema, M.D. | Diagnostiskt Centrum Hud, Konsult LBG vard AB | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Advanced Clinic | Gothenburg | 41122 | Sweden | |||
| Svenska Hudkliniker Karlstad |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Secondary endpoint evaluated improvement by GAIS score | GAIS (Global Aesthetic Improvement Scale) score at 1- months, 3 months and 6 months post-treatment, as assessed by the treating investigator and blinded evaluator. Scoring from 1-5 equals "very much improved," "much improved," "improved," "unchanged," and "worsened," | At Visit 1 (Day 0), Visit 2 (Day 30), Visit 3 (Day 90) and Visit 4 (Day 180) |
| Secondary endpoint by evaluating improvement by GAIS | GAIS (Global Aesthetic Improvement Scale) score at 1- month, 3- months and 6 months post-treatment, as assessed by the subject. Scoring from 1-5 equals "very much improved," "much improved," "improved," "unchanged," and "worsened," | At Visit 1 (Day 0), Visit 2 (Day 30), Visit 3 (Day 90) and Visit 4 (Day 180) |
| Secondary endpoint evaluating treatment related Adverse Events | Treatment related adverse events and injection site reactions reported after touch-up should be similar to those reported after initial treatment. | 30 days after injection of initial treatment (Day 0-30) and optional touch-up (Day 30-60) |
| Secondary endpoint by instrumental evaluation of lips by image analysis. | Change in lip compared to baseline will be measured after treatment, as well as at 1-month, 3-months and 6 months post-treatment visits. Instrumental evaluation of lips will be done by image analysis. A descriptive analysis of the semi.quantative change from baseline and after treatment will be done. Exploration of correction with other endpoints or measurements such as GAIS will be performed posthoc. | From pre-intervention baseline, to post-treatment at Day 1, 30, 90 and 180 respectively |
| Secondary endpoint evaluated outcome by GAIS score | GAIS (Global Aesthetic Improvement Scale) score at 1- months, 3 months and 6 months post-treatment, as assessed by the treating investigator and blinded evaluator. Scoring from 1-5 equals "very much improved," "much improved," "improved," "unchanged," and "worsened," | At Visit 1 (Day 0), Visit 2 (Day 30), Visit 3 (Day 90) and Visit 4 (Day 180) |
| Karlstad |
| 65225 |
| Sweden |
| Hansa Estetik | Malmö | 21138 | Sweden |
| Svenska Hudkliniker | Stockholm | 114 46 | Sweden |
| Dr Filip | Stockholm | 11456 | Sweden |
| Peri Estetik | Västerås | 72212 | Sweden |